Kala Pharmaceuticals (KALA) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Kala Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 7, 2020 7:00 AM EDT-- Announced Positive Results from STRIDE 3 Clinical Trial of EYSUVIS in March 2020, Demonstrating Statistically Significant Results for Primary and Key Secondary Endpoints --
-- EYSUVISTM NDA Resubmitted on April 30th; Potential Approval and Launch Before Year-End --
-- Raised $146.9 Million in Gross Proceeds from Sales of Common Stock in Early 2020 --
-- 1Q 2020 INVELTYS® Revenue of $1.1 Million --
-- Conference Call and Webcast at 8:00 a.m. ET
WATERTOWN, Mass.--(BUSINESS WIRE)--
Kala... More
